poisar

Stocks · News reference

Royalty Pharma Announces 2030 Financial Outlook

Fiscal.ai

Royalty Pharma has released a long-term financial outlook targeting over $4.7 billion in annual portfolio receipts and more than $7.50 in portfolio cash flow per share by 2030.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Zacks Investment ResearchNa

    Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

    The iShares U.S. Pharmaceuticals ETF (IHE) is reviewed as a reasonable option for investors seeking broad exposure to the Healthcare-Pharma sector. With $1.69 billion in assets and a 0.37% expense ratio, the fund has delivered strong year-to-date returns of 28.8% and one-year returns of 35.48%. However, it carries higher risk with a beta of 0.47 and standard deviation of 17.13%. Top holdings include Eli Lilly (26.88%), Johnson & Johnson, and Royalty Pharma, with the top 10 holdings representing 81.09% of assets.

  2. SEC EDGARSEC EDGAR

    8-K filing — Royalty Pharma plc (RPRX)

    Filed: 2026-11-04 AccNo: 0001802768-26-000026 Size: 501 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

  3. The Motley FoolThomas Niel

    Should You Buy Royalty Pharma Stock Before Nov. 4?

    Royalty Pharma shares have rallied toward 52-week highs ahead of Q3 2026 earnings on Nov. 4, but investors should focus on long-term prospects rather than short-term earnings catalysts. Analysts expect 8.7% sales growth and flat earnings, with potential upside from positive pipeline updates on cancer treatments and other drug candidates, though negative news on pelacarsen could weigh on the stock.